Asset Details
Do you wish to reserve the book?
Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism
Do you wish to request the book?
Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism
2019
Overview
Macrophages contribute to the pathogenesis of rheumatoid arthritis (RA). They can display different states of activation or \"polarization,\" notably the so-called inflammatory \"M1\" and the various alternative \"M2\" polarizations, characterized by distinct functions. Data regarding the effects of RA anti-cytokine biological disease-modifying anti-rheumatic drugs (bDMARDs) on macrophage polarization are scarce. We aimed to assess
modulation of macrophage polarization by bDMARDs targeting pro-inflammatory cytokines in RA. We generated monocyte derived macrophages using blood samples from 20 RA patients with active RA and 30 healthy controls. We evaluated
the impact on M1 inflammatory macrophages of: etanercept (ETA), adalimumab (ADA), certolizumab (CZP), tocilizumab (TCZ), and rituximab (RTX). We assessed the impact on macrophage polarization using flow cytometry and RTqPCR to study the expression of surface markers and perform functional studies of cytokine production, phagocytosis, and negative feedback control of inflammation. Among evaluated bDMARDs, anti-TNF agents modulated the polarization of inflammatory macrophages by decreasing inflammatory surface markers (CD40, CD80) and favoring alternative markers (CD16, CD163, MerTK). Anti-TNF agents also induced alternative functions in macrophages activated in inflammatory condition with (i) the inhibition of inflammatory cytokines (TNF, IL-6, IL-12), (ii) an increase in phagocytosis. These findings were mechanistically related to an increase in early IL-10 production, responsible for higher negative feedback control of inflammation involving SOCS3 and Gas6. This IL-10 effect was STAT3-dependent. Anti-TNF agents not only inhibit
inflammatory functions of macrophages, but also favor resolution of inflammation through polarization toward alternative features specifically involving the IL-10/STAT3 axis.
Publisher
Frontiers Media SA,Frontiers,Frontiers Media S.A
Subject
/ Arthritis, Rheumatoid - diagnosis
/ Arthritis, Rheumatoid - immunology
/ Arthritis, Rheumatoid - metabolism
/ Arthritis, Rheumatoid - therapy
/ Cloning
/ Feedback
/ Female
/ Humans
/ Kinases
/ Labeling
/ Leukocytes, Mononuclear - drug effects
/ Leukocytes, Mononuclear - immunology
/ Leukocytes, Mononuclear - metabolism
/ Macrophage Activation - immunology
/ Male
/ Software
/ STAT3
/ STAT3 Transcription Factor - metabolism
/ TNF
/ Tumor Necrosis Factor-alpha - antagonists & inhibitors
